KLOW Peptide Blend Explained: What KPV Adds to GLOW

KPV takes its name from its three amino acids, lysine-proline-valine. It is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), corresponding to residues 11–13 of the full hormone, and is sometimes written as α-MSH(11-13) in the literature.^[3]

That positioning matters because α-MSH signals mainly through the melanocortin-1 receptor (MC-1R), which is also what gives it a pigmentation effect. A 2010 review states that KPV lacks the sequence motif needed to bind any known melanocortin receptor, yet retains almost all of α-MSH's anti-inflammatory activity without the pigmentary action — one reason it is studied separately from receptor-agonist peptides such as the melanotans.^[5]

In human keratinocyte cell cultures, KPV did not raise cyclic AMP the way α-MSH does through MC-1R, and produced a measurable calcium response only when the cells were also treated with an adenosine-pathway compound. The authors concluded it was not yet clear whether KPV signals through MC-1R at all.^[3]

The clearest evidence that KPV acts independently of melanocortin receptors comes from a 2003 study in mice. Systemic KPV reduced immune-cell accumulation in a model of crystal-induced peritonitis, and that effect was not blocked by a melanocortin-3/4 receptor antagonist and still occurred in mice with a non-functional MC-1 receptor. In the same study, KPV — unlike α-MSH — did not increase cyclic AMP or suppress cytokine release from macrophages in cell culture; the authors concluded KPV was more likely to act through inhibition of interleukin-1β activity than through melanocortin receptors.^[4]

The largest body of KPV research is in the gut. A 2008 study found that human intestinal epithelial cell lines and T cells took up KPV via PepT1, a transporter also induced in the colon during inflammatory bowel disease, and that nanomolar concentrations of KPV inhibited NF-κB and MAP-kinase inflammatory signalling. In the same study, mice given KPV in their drinking water had less colitis after two different chemical triggers (DSS and TNBS), measured by tissue damage and pro-inflammatory gene expression.^[6]

A separate 2008 study tested KPV in two further mouse models of colitis and in mice bred with a non-functional MC-1 receptor. KPV-treated mice recovered body weight faster and had less inflammation on tissue and enzyme measures in both colitis models; in the receptor-deficient mice, KPV treatment kept every treated animal alive through an otherwise fatal course of colitis. The authors described the effect as at least partly independent of MC-1R signalling.^[7]

A 2025 review of tripeptides in wound healing describes KPV mainly in hydrogel form: KPV-loaded hydrogels are reported to reduce inflammation, support tissue regeneration and act against MRSA in the studies it surveyed. The same review covers GHK-based formulations separately, as a different tripeptide with its own wound-healing literature — the two are discussed side by side, not as a tested combination.^[8]

The newest KPV research points somewhere unrelated to inflammation or skin. A study published in August 2026 treated mouse pre-adipocyte cells with KPV and reported dose-dependent suppression of fat-cell differentiation, cutting lipid accumulation by about 55% at the highest concentration tested. It is a single cell-culture study with no animal or human follow-up yet, so it shows a research direction rather than an established effect.^[9]

Not as a four-peptide combination. A PubMed search combining GHK or copper peptide, BPC-157, thymosin beta-4 or TB-500, and KPV, run in September 2026, returned zero records. Widening the search to KPV alongside any single one of the other three components returns only two records, and both are broad reviews — one surveying compounding-safety standards for many research peptides, the other the wound-healing tripeptide review already cited above — rather than a test of any two of the four together.^[1][8]

Our GLOW article covers the one published controlled test that combined two of the three shared components; we found no study that added KPV, or any fourth peptide, to that combination.^[1][2]

Every additional peptide in a mixture adds another identity to confirm and another quantity to measure. A single HPLC purity percentage for a four-peptide blend cannot describe any one component on its own; mass-spectrometry identity testing has to resolve four separate molecules, and each needs its own concentration figure. The verification burden documented for the three-peptide GLOW blend does not shrink when a fourth peptide is added — it grows.

Stability is a second unknown that also compounds. GLOW's own stability question — how GHK-Cu, BPC-157 and TB-500 behave stored together — has no published answer; we found no published data on a four-peptide mixture that also includes KPV, freeze-dried or in solution.^[1]

The regulatory status of GHK-Cu, BPC-157 and TB-500 — including their absence from EMA-authorised medicines and their place on WADA's Prohibited List — is covered in our GLOW article; we have not repeated that research here. For KPV specifically, the clearest sourced fact is from the FDA.

The FDA's list of bulk drug substances that may present significant safety risks includes an entry for KPV. It states that the FDA has not identified human exposure data for drug products containing KPV via any route of administration, and that the agency lacks information on whether the substance would cause harm if administered to humans.^[10]

Peptyds does not sell a pre-mixed KLOW blend. GHK-Cu, BPC-157, TB-500 and KPV are supplied as separate lyophilised research compounds for in-vitro laboratory work, each with its own batch certificate for identity and purity, linked from its product page.

That mirrors the evidence above: three of the four components already have a dedicated article on this site, KPV has a separate and mostly preclinical literature of its own, and no published research has tested the four together. Nothing on this page is guidance for personal use.^[1]